Wire · opportunities
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
Eli Lilly announced positive Phase 3 trial data for retatrutide, its next-generation obesity drug targeting three metabolic pathways, with weight loss ranging from 20.8% to 22.6% across patient cohorts; the company plans to submit an FDA biologics application in Q1 2027.
This Wire brief sits within Fusion42's coverage of Digital Health, and 3 sources have reported it between 23 Jul 2026 and 4 Aug 2026.
◆ ◆ The Wire takeaway
Lilly's triple-hormone drug hits the regulatory finish line in nine months. If you're selling to obesity clinics, pharmacies or digital health platforms, the market is about to split between GLP-1-only operators and triple-hormone practices—and clinics will need new workflows, supply chains and staffing to handle the migration.
◆ Coverage
3 sources · first reported 23 Jul 2026 · latest 4 Aug 2026
◆ Related on Wire
◆ Topics